The SEC reviewed Valeant Pharmaceuticals’ use of adjusted “non-GAAP” financial measures, and criticized Valeant’s disclosures at one point as “potentially misleading,” according to documents.
from WSJ.com: US Business http://ift.tt/1OUQmeB
via IFTTT
No comments:
Post a Comment